ChromaDex (CDXC) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. FND
9. DASH
10. GILD

Go back to ChromaDex (CDXC) Misses Q4 EPS by 4c

ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34%

March 16, 2017 4:10 PM EDT

IRVINE, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the financial results for the year ended Dec. 31, 2016.

We finished 2016 on a strong note, generating 29% year over year revenue growth during the fourth quarter, commented Frank Jaksch, Jr., CEO and co-founder of ChromaDex. We achieved record full year revenue of $26.8 million in 2016, driven by continued adoption of NIAGEN® branded nicotinamide riboside (NR).... More